News

UConn gene discovery moves closer to treating neuromuscular disease, holds promise for weight loss
have recently been testing myostatin inhibitors in phase three trials in patients with spinal muscular atrophy, or SMA, a ...
pharmaphorum5d
Roche joins others in dropping myostatin inhibitor for DMD
The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...
Nasdaq3d
Northstrive Biosciences Receives FDA Feedback Supporting IND Filing for EL-22 in Obesity Treatment
A New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein, BLS-M22, Int. J. Mol. Sci. 2022, 23, 9059.
pharmaphorum8d
Pfizer takes muscular dystrophy drug into phase II
A few years later, a clinical trial of a myostatin inhibitor called stamulumab (MYO-029) developed by Wyeth (which was acquired by Pfizer in 2009) showed some promise in early trials but was ...
Nasdaq1mon
Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA to Discuss EL-22 for Muscle Preservation in Obesity Treatment
A New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein, BLS-M22, Int. J. Mol. Sci. 2022, 23, 9059.